Major Funding Bolsters AI in Cancer Diagnostics
Helsinki-based life-science company Aiforia has secured €20 million in financing from the European Investment Bank (EIB) to accelerate product development and commercial expansion of its AI-powered pathology solutions. Aiforia’s platform applies deep learning to high-resolution tissue images, assisting pathologists with automated detection, quantification and classification of tumors.
Accelerating Precision in Patient Care
The EIB funding is earmarked for scaling Aiforia’s digital tissue analysis capabilities, expanding clinical validation studies, and broadening market access for CE-IVD marked solutions intended for diagnostic use. Aiforia’s tools are designed to identify tumour regions, measure biomarkers and standardize readouts that can reduce variability in pathology interpretation. According to CEO Jukka Tapaninen, the capital will support work to move AI models from research settings into routine diagnostic workflows and to complete regulatory and quality processes needed for wider clinical deployment.
Clinically validated CE-IVD marking signals that products meet regulatory requirements for diagnostic use in Europe, supporting adoption in hospital laboratories and pathology networks. Improved detection and reproducibility in tissue analysis can shorten diagnostic timelines, inform treatment decisions and potentially improve patient outcomes through more consistent pathology reporting.
European Innovation and Global Reach
The EIB frames the investment as part of a broader effort to keep European life sciences competitive in digital health and medical AI. EIB Vice-President Karl Nehammer highlighted the bank’s role in helping home-grown companies scale technologies that have clinical and commercial relevance across markets.
Aiforia began as a University of Helsinki spin-off and has expanded internationally, supplying software and services to clinical and research laboratories worldwide. The new financing positions the company to accelerate product rollouts, expand commercial operations and deepen clinical evidence — a step that could strengthen Europe’s position in the global market for AI-enabled diagnostics.
For healthcare providers and investors, the transaction underscores a trend: targeted public finance is moving from proofs of concept toward real-world deployment of AI tools that support pathology and precision oncology.
